Amarin Corp Plc (AMRN)

[HinduKush]

sts
(1)The USPTO examiner considered all of these factors: the special TG>500mg/dl population, the LDL neutrality of EPA even in TG>500 and the unique ApoB effects in this unique population (Tg>500 mg/dl). Please see my prior post(s) on ApoB and the USPTO examiner's opinion in granting the actual MARINE patent(s).
(2)Heineke was well aware of all of this...As an academic lipidologist POSA you would have to be blind deaf and dumb not to acknowledge it.
(3) The y axis is the lipolytic rate of the enzymes that breakdown VLDL to IDL and thence to LDL. Like all rate limiting pathways in chemistry the kinetics are saturatable, and saturate at a critical concetration Tg~500 mg/dl. In this case that saturation of the lipolytic reaction occurrs at or around (and definitely above) 500mg/dl. Any TG lowering drug (eg Lovaza) that relies on enhancing lipolysis would work until the enzymes saturate at 500mg/dl TG concentration after that LDL would accumulate in excess. EPA as IPE not only stimulates lipolysis but also modulates (inhibits)the hepatic synthetic pathways that feed VLDL into teh circulation...hence the lack of rise in LDL with concomitant TG lowering.
HK
For a more detailed analysis:
https://investorshub.advfn.com/uimage/uploads/2020/6/25/nekkj500_MG_LIMIT.png